Beta Drugs: Machine Readable / legible copy of Financial Results for the period ended 30-Sep-2026'

What happened

Beta Drugs (BETA) filed a disclosure with the exchanges on 2 November 2026 at 04:10 PM titled "Machine Readable / legible copy of Financial Results for the period ended 30-Sep-2026'".

From the filing: "Beta Drugs Limited has informed the Exchange regarding 'Machine Readable / legible copy of Financial Results for the period ended 30-Sep-2026'."

Company snapshot

Beta Drugs is a small-cap company, with a market value of about ₹1,994 crore.

The stock last traded at ₹1,798.4, against a 52-week range of ₹990.1–₹2,807.9 (36.0% below the high).

Before this filing the shares had moved −12.9% over the month and −18.4% over three months. Average daily turnover over the last 20 sessions was about ₹16.03 crore.

Promoters held 59.10% at the end of Q1 FY27. Foreign institutions owned 1.02% and domestic institutions 6.23%.

What history shows

This is not the company's first results disclosure: BCEIE has 1 earlier filing of this kind on record since May 2026.

Market-wide, 10,143 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.

Past reactions describe what happened before; they are not a forecast.

What to watch

• Management commentary, margins and order book or guidance in the investor presentation.

In the news

Recent coverage elsewhere (links open the original publisher):

• Beta Drugs Ltd (NSE:BETA) Q2 2027 Earnings Call Highlights: 29% Revenue Surge, 45% PAT Jump and ... — Yahoo Finance, 23 Oct 2026
• Beta Drugs Reports Q2 Consolidated Net Profit of ₹19.3 Crore on Revenue of ₹137 Crore — Sahi, 22 Oct 2026
• Beta Drugs (BETA) Share Price Rises 8.42% to Rs 2,097.00 Today — Univest, 28 Oct 2026
• Beta Drugs NSE:BETA Q2 FY27 Results Board Meeting Outcome — Kalkine India, 22 Oct 2026
• Beta Drugs Q2 Results FY27: PAT Jumps 51.8% to Rs 18.55 Cr, Revenue Rs 137.49 Cr — Univest, 22 Oct 2026

Source

• Exchange filing (PDF)